Stockhead’s Ashtyn Hiron sits down with AROA Biosurgery (ASX:ARX) CEO Dr. Brian Ward to get the short end of the long story on the company’s latest news.

Aroa Biosurgery’s Enivo system may reduce secondary complications in mastectomies, with positive results emerging from its pilot clinical trial of the device showing promise in the all-important management of dead space. Dead space refers to the open space created by surgical separation or excision of soft tissue.

The system could change how patients are treated post-operation but could ask be utilised in other surgeries like treating hernias, breast reconstruction, traumas, tumour removal and orthopaedics.

Tune in to hear AROA Biosurgery’s Dr. Brian Ward on how this could be used in other surgeries, how it works and more.

Read MoreAusbiotechHealth

Featured Companies

You might be interested in